Skip to main content

Advertisement

SpringerLink
Log in

Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway

  • Original Paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Background

The metabolic syndrome has been suggested as a unifying link between a “western” lifestyle and an increased prostate cancer risk.

Methods

We assessed the associations of components of the metabolic syndrome with prostate cancer in a prospective cohort based on 29,364 Norwegian men followed up for prostate cancer incidence and mortality from 1995–1997 to the end of 2005 in the second Nord Trøndelag Health Study (HUNT 2).

Results

During a mean 9.3 years follow-up, 687 incident prostate cancers were diagnosed, and 110 men died from prostate cancer. There was little evidence that baseline BMI, waist circumference, waist–hip ratio, total or HDL-cholesterol, triglycerides, presence of the metabolic syndrome, diabetes, antihypertensive use, or cardiovascular disease were associated with incident or fatal prostate cancer. There was weak evidence that raised blood pressure was associated with an increased risk: for each SD (12 mm) increase in diastolic blood pressure, there was an 8% (95% CI = 1–17%; p = 0.04) increased risk of incident prostate cancer.

Conclusions

We found little evidence to support the hypothesis that the metabolic syndrome or its components explains higher prostate cancer mortality rates in countries with a “western” diet and lifestyle. The positive association of blood pressure with prostate cancer warrants further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM (2004) International variation. Oncogene 23(38):6329–6340. doi:10.1038/sj.onc.1207726

    Article  PubMed  CAS  Google Scholar 

  2. Yatani R, Shiraishi T, Nakakuki K et al (1988) Trends in frequency of latent prostate carcinoma in Japan from 1965–1979 to 1982–1986. J Natl Cancer Inst 80(9):683–687. doi:10.1093/jnci/80.9.683

    Article  PubMed  CAS  Google Scholar 

  3. Post PN, Straatman H, Kiemeney LA, Coebergh JW (1999) Increased risk of fatal prostate cancer may explain the rise in mortality in The Netherlands. Int J Epidemiol 28(3):403–408. doi:10.1093/ije/28.3.403

    Article  PubMed  CAS  Google Scholar 

  4. Janssen F, Kunst AE, for The Netherlands Epidemiology, Demography Compression of Morbidity research group (2005) Cohort patterns in mortality trends among the elderly in seven European countries, 1950–99. Int J Epidemiol 34(5):1149–1159. doi:10.1093/ije/dyi123

    Article  PubMed  CAS  Google Scholar 

  5. Yu H, Harris RE, Gao YT, Gao R, Wynder EL (1991) Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States. Int J Epidemiol 20(1):76–81. doi:10.1093/ije/20.1.76

    Article  PubMed  CAS  Google Scholar 

  6. Hsing AW, Devesa SS (2001) Trends and patterns of prostate cancer: What do they suggest? Epidemiol Rev 23(1):3–13

    PubMed  CAS  Google Scholar 

  7. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37(12):1595–1607. doi:10.2337/diabetes.37.12.1595

    Article  PubMed  CAS  Google Scholar 

  8. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, for the Conference Participants (2004) Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition. Circulation 109(3):433–438. doi:10.1161/01.CIR.0000111245.75752.C6

    Article  PubMed  Google Scholar 

  9. Giovannucci E (2003) Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 35(11/12):694–704

    Google Scholar 

  10. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH (2002) Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev 3(4):303–308. doi:10.1046/j.1467-789X.2002.00081.x

    Article  PubMed  CAS  Google Scholar 

  11. Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-1, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353. doi:10.1016/S0140-6736(04)16044-3

    Article  PubMed  CAS  Google Scholar 

  12. Fan W, Yanase T, Morinaga H et al (2007) Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 282(10):7329–7338. doi:10.1074/jbc.M610447200

    Article  PubMed  CAS  Google Scholar 

  13. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 287(3):356–359. doi:10.1001/jama.287.3.356

    Article  PubMed  Google Scholar 

  14. Hammarsten J, Hogstedt B (2004) Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 13(1):47–55. doi:10.1080/08037050310025735

    Article  PubMed  CAS  Google Scholar 

  15. Freedland SJ, Platz EA (2007) Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29:88–97. doi:10.1093/epirev/mxm006

    Article  PubMed  Google Scholar 

  16. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–1638. doi:10.1056/NEJMoa021423

    Article  PubMed  Google Scholar 

  17. Wright ME, Chang SC, Schatzkin A et al (2007) Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109(4):675–684. doi:10.1002/cncr.22443

    Article  PubMed  Google Scholar 

  18. Pischon T, Boeing H, Weikert S et al (2008) Body size and risk of prostate cancer in the european prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 17(11):3252–3261. doi:10.1158/1055-9965.EPI-08-0609

    Article  PubMed  Google Scholar 

  19. Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA (2007) Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 109(5):875–881. doi:10.1002/cncr.22461

    Article  PubMed  Google Scholar 

  20. Wuermli L, Joerger M, Henz S et al (2005) Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 8(4):316–320. doi:10.1038/sj.pcan.4500834

    Article  PubMed  CAS  Google Scholar 

  21. Lund Haheim L, Wisloff TF, Holme I, Nafstad P (2006) Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 164(8):769–774. doi:10.1093/aje/kwj284

    Article  PubMed  CAS  Google Scholar 

  22. Browning DR, Martin RM (2007) Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120(4):833–843. doi:10.1002/ijc.22366

    Article  PubMed  CAS  Google Scholar 

  23. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL (2001) Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 11(8):534–542. doi:10.1016/S1047-2797(01)00246-0

    Article  PubMed  CAS  Google Scholar 

  24. Gann PH, Daviglus ML, Dyer AR, Stamler J (1995) Heart rate and prostate cancer mortality: results of a prospective analysis. Cancer Epidemiol Biomarkers Prev 4(6):611–616

    PubMed  CAS  Google Scholar 

  25. Freeman MR, Solomon KR (2004) Cholesterol and prostate cancer. J Cell Biochem 91(1):54–69. doi:10.1002/jcb.10724

    Article  PubMed  CAS  Google Scholar 

  26. Friedman GD (1997) Blood pressure and heart rate: no evidence for a positive association with prostate cancer. Ann Epidemiol 7(7):486–489. doi:10.1016/S1047-2797(97)00083-5

    Article  PubMed  CAS  Google Scholar 

  27. Bidoli E, Talamini R, Bosetti C et al (2005) Macronutrients, fatty acids, cholesterol and prostate cancer risk. Ann Oncol 16(1):152–157. doi:10.1093/annonc/mdi010

    Article  PubMed  CAS  Google Scholar 

  28. Niemi M, Kervinen K, Kiviniemi H et al (2000) Apolipoprotein E phenotype, cholesterol and breast and prostate cancer. J Epidemiol Community Health 54(12):938–939. doi:10.1136/jech.54.12.938

    Article  PubMed  CAS  Google Scholar 

  29. MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG (2003) Body size and composition and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 12(12):1417–1421

    PubMed  Google Scholar 

  30. MacInnis RJ, English DR (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17(8):989–1003. doi:10.1007/s10552-006-0049-z

    Article  PubMed  Google Scholar 

  31. Borugian MJ, Spinelli JJ, Sun Z et al (2007) Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16(10):2164–2165. doi:10.1158/1055-9965.EPI-07-0495

    Article  PubMed  CAS  Google Scholar 

  32. Moore SC, Leitzmann MF, Weinstein SJ et al (2007) Insulin resistance-related gene polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16(6):1315–1317. doi:10.1158/1055-9965.EPI-07-0191

    Article  PubMed  CAS  Google Scholar 

  33. National Cholesterol Education Program Expert Panel (2002) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106(25):3143

    Google Scholar 

  34. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE (2002) Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 87(3):978–982. doi:10.1210/jc.87.3.978

    Article  PubMed  CAS  Google Scholar 

  35. Kom EL, Graubard BI, Midthune D (1997) Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 145(1):72–80

    Google Scholar 

  36. Zuccolo L, Harris R, Gunnell D et al (2008) Height and prostate cancer risk: a large nested case–control study (ProtecT) and meta-analysis. Cancer Epidemiol Biomarkers Prev 17(9):2325–2336. doi:10.1158/1055-9965.EPI-08-0342

    Article  PubMed  CAS  Google Scholar 

  37. Nilsen TI, Romundstad PR, Vatten LJ (2006) Recreational physical activity and risk of prostate cancer: a prospective population-based study in Norway (the HUNT study). Int J Cancer 119(12):2943–2947. doi:10.1002/ijc.22184

    Article  PubMed  CAS  Google Scholar 

  38. Makinen T, Karhunen P, Aro J, Lahtela J, Maattanen L, Auvinen A (2008) Assessment of causes of death in a prostate cancer screening trial. Int J Cancer 122(2):413–417. doi:10.1002/ijc.23126

    Article  PubMed  CAS  Google Scholar 

  39. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT (2000) Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 92(8):613–621. doi:10.1093/jnci/92.8.613

    Article  PubMed  CAS  Google Scholar 

  40. Miller AB, Yurgalevitch S, Weissfeld L (2000) Death review process in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21(6, supplement 1):400S–406S. doi:10.1016/S0197-2456(00)00095-7

    Article  PubMed  CAS  Google Scholar 

  41. Hernes E, Harvei S, Glattre E, Gjertsen F, Fossa SD (2005) High prostate cancer mortality in Norway: influence of cancer registry information? APMIS 113(7–8):542–549. doi:10.1111/j.1600-0463.2005.apm_245.x

    Article  PubMed  CAS  Google Scholar 

  42. Harvei S, Tretli S, Langmark F (1996) Quality of prostate cancer data in the cancer registry of Norway. Eur J Cancer 32(1):104–110. doi:10.1016/0959-8049(95)00501-3

    Article  Google Scholar 

  43. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC (2007) Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 121(7):1571–1578. doi:10.1002/ijc.22788

    Article  PubMed  CAS  Google Scholar 

  44. Albertsen PC, Hanley JA, Fine J (2005) 20-Year outcomes following conservative management of clinically localized prostate cancer. J Am Med Assoc 293(17):2095–2101. doi:10.1001/jama.293.17.2095

    Article  CAS  Google Scholar 

  45. Hsing AW, Sakoda LC, Chua SC Jr (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86(3):S843–S857

    PubMed  Google Scholar 

  46. Stattin P, Kaaks R (2003) Re: insulin resistance and prostate cancer risk. J Natl Cancer Inst 95(14):1086–1087

    Article  PubMed  Google Scholar 

  47. Stattin P, Soderberg S, Hallmans G et al (2001) Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 86(3):1341–1345. doi:10.1210/jc.86.3.1341

    Article  PubMed  CAS  Google Scholar 

  48. Stocks T, Lukanova A, Rinaldi S et al (2007) Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 120(12):2678–2686. doi:10.1002/ijc.22587

    Article  PubMed  CAS  Google Scholar 

  49. Tande AJ, Platz EA, Folsom AR (2006) The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164(11):1094–1102. doi:10.1093/aje/kwj320

    Article  PubMed  Google Scholar 

  50. Ness KK, Oakes JM, Punyko JA, Baker KS, Gurney JG (2005) Prevalence of the metabolic syndrome in relation to self-reported cancer history. Ann Epidemiol 15(3):202–206. doi:10.1016/j.annepidem.2004.07.092

    Article  PubMed  Google Scholar 

  51. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT (2004) Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 13(10):1646–1650

    PubMed  CAS  Google Scholar 

  52. Dalton M, Cameron AJ, Zimmet PZ et al (2003) Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J Intern Med 254(6):555–563. doi:10.1111/j.1365-2796.2003.01229.x

    Article  PubMed  CAS  Google Scholar 

  53. Karter AJ, D’Agostino RB, Mayer-Davis EJ et al (2005) Abdominal obesity predicts declining insulin sensitivity in non-obese normoglycaemics: the insulin resistance atherosclerosis study (IRAS). Diabetes Obes Metab 7(3):230–238. doi:10.1111/j.1463-1326.2004.00441.x

    Article  PubMed  CAS  Google Scholar 

  54. Ohlson LO, Larsson B, Svardsudd K et al (1985) The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 34(10):1055–1058. doi:10.2337/diabetes.34.10.1055

    Article  PubMed  CAS  Google Scholar 

  55. Richelsen B, Pedersen SB (1995) Associations between different anthropometric measurements of fatness and metabolic risk parameters in non-obese, healthy, middle-aged men. Int J Obes Relat Metab Disord J Int Assoc Stud Obes 19(3):169–174

    CAS  Google Scholar 

  56. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ (2001) Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10(4):345–353

    PubMed  CAS  Google Scholar 

  57. Andersson SO, Wolk A, Bergstrom R et al (1997) Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 89(5):385–389. doi:10.1093/jnci/89.5.385

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The hypothesis was developed by RMM, DG, and LV. TILN did the statistical analysis with advice from PR. RMM wrote the first draft of the manuscript with input on the methods from TILN. RMM, DG, LV, PR, and TILN all critically commented on and edited earlier drafts and approved the final version of the article. TILN had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Conflicts of interest

None to declare.

Funding

The study design, conduct, and data collection were supported by the Norwegian Research Council. Analysis and interpretation of the data, preparation, review, and approval of the article were unfunded.

Author information

Authors and Affiliations

  1. Department of Social Medicine, University of Bristol, Bristol, BS8 2PR, UK

    Richard M. Martin & David Gunnell

  2. Department of Public Health, Norwegian University of Science and Technology, Trondheim, Norway

    Lars Vatten & Pål Romundstad

  3. International Agency for Research on Cancer, Lyon, France

    Lars Vatten

  4. Human Movement Science Program, Norwegian University of Science and Technology, Trondheim, Norway

    Tom I. L. Nilsen

Authors
  1. Richard M. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lars Vatten
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Gunnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pål Romundstad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tom I. L. Nilsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard M. Martin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, R.M., Vatten, L., Gunnell, D. et al. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 20, 1181–1192 (2009). https://doi.org/10.1007/s10552-009-9319-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-009-9319-x

Keywords

Search

Navigation